<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20894" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>ED50</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kenny</surname>
            <given-names>Brian J.</given-names>
          </name>
          <aff>Kansas City University of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McPhee</surname>
            <given-names>Arthur S.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian Kenny declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arthur McPhee declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>9</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20894.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">The ED50 is the dose of a medication that produces a specific effect in 50% of the population that&#x000a0;has been administered that dose. This metric can be used clinically by clinicians for a particular drug effect. However, depending on the risk-benefit analysis, clinicians may use a different dosage for their intended outcome. The toxic dose in 50% of the population is called TD50; the ED50 should be much less than the TD50, as this would indicate an effective medication at a lower dose.<xref ref-type="bibr" rid="article-20894.r1">[1]</xref>&#x000a0;The ED50 for a particular medication&#x000a0;is derived from a dose-response curve, in which the ED50 is at the dosage (x-axis), where there is 50% of the desired response (y-axis).</p>
        <p>The ED50 should be used as a clinical starting point for clinicians when prescribing medications, as dosage adjustments are made to balance efficacy and toxicity. The E-max would be equivalent to the maximum effect the drug may have. It is important to remember that as dosages increase, the risk for toxicities will increase and may not be directly proportionate. Each patient requires individualized treatment goals and should be monitored to ensure the lowest effective dose possible, especially for long-term treatment.</p>
        <p>There are two dose-response curve (DRC) forms: graded and quantal. Graded answers the question, &#x02018;How much?&#x02019; whereas quantal DRC answers, &#x02018;Yes or no?&#x02019; The ED50 may change depending on the question the clinician is trying to answer; using the recommended ED50 as a starting point is recommended, making adjustments based on the clinical outcomes.</p>
      </sec>
      <sec id="article-20894.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Research shows that even when manufacturers set dose estimation guidelines, it has an insignificant impact on what dose clinicians prescribe. Another overlooked aspect of the ED50 is the variation depending on&#x000a0;a patient's weight, height, fat content, pharmacokinetics, and pharmacodynamics.<xref ref-type="bibr" rid="article-20894.r1">[1]</xref></p>
        <p>ED50 for medications and the recommended dosages based on clinical studies are derived from surrogate endpoints (e.g., blood pressure after taking medication) rather than the drug's long-term effects on the body.<xref ref-type="bibr" rid="article-20894.r2">[2]</xref></p>
        <p>Clinical studies have shown that mortality is often deemed too uncommon or too small of an endpoint to be particularly interesting for a medication. However, in a large patient population, medications with substantial clinical benefits may also lead to severe consequences and death. An example of this is digoxin, which has had efficacy in heart failure and atrial fibrillation but caused a net increase in mortality when administered in standard dosages.<xref ref-type="bibr" rid="article-20894.r1">[1]</xref></p>
        <p>Optimal dosing balances efficacy and safety. Dosing in psychiatry is challenging due to subjective factors, and the dosage can vary significantly. The usual recommended daily dose of desvenlafaxine is 50 mg, but doses as high as 400 mg have been documented, exceeding the effective dosage (ED50). This practice increases the incidence of adverse drug reactions (ADRs) without clear therapeutic benefits. The absence of significant clinical advantage at increased doses of first-generation antipsychotics and the risk of severe adverse effects. It is important to note that higher doses may be necessary depending on the clinical scenario, but it is essential to comprehend ED50 for safe prescribing.<xref ref-type="bibr" rid="article-20894.r3">[3]</xref></p>
      </sec>
      <sec id="article-20894.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>When dosing drugs for significant periods, the dosage for the desired effect must be monitored to ensure that the patient does not approach the toxic dose.<xref ref-type="bibr" rid="article-20894.r4">[4]</xref>&#x000a0;Knowing the drug's ED50 is very useful in avoiding potential adverse outcomes.</p>
        <p>A recent study found that prescription medications have contributed to over 10% of hospital admissions and over 15% of hospital mortality.<xref ref-type="bibr" rid="article-20894.r5">[5]</xref>&#x000a0;It is important to clarify that not all of these cases arise from using higher doses than necessary for the intended efficacy. Prescriptions with high dosages should be consistently reviewed periodically to ensure they do not lead to potentially toxic drug exposure levels.&#x000a0;Research has found that&#x000a0;prescribing&#x000a0;medications such as aspirin and statins at dosages near their ED50 is the most effective from a preventative standpoint. For example, an 81 mg aspirin dosage after a first clinical heart event is just as effective as dosages of over 100 mg.<xref ref-type="bibr" rid="article-20894.r6">[6]</xref>&#x000a0;</p>
        <p>It is essential to consider the clinical endpoints for patients, as alterations in weight and age can affect the ED50 of medications. Based on established guidelines, clinicians often aim to meet specific metrics, such as HbA1c. However, failure to consider ED50 can result in patients receiving medication doses that exceed their toxicity threshold, which may be a standard dose for another patient.<xref ref-type="bibr" rid="article-20894.r1">[1]</xref></p>
        <p>The therapeutic index (TI) should also be considered for better comprehension of ED50 (TI = TD50/ED50).&#x000a0;LD50 is the lethal drug dose for 50% of the population, usually utilized in preclinical (animal) studies.<xref ref-type="bibr" rid="article-20894.r7">[7]</xref>&#x000a0;Medications with a lower therapeutic index (TI), like warfarin, lithium, and theophylline, require close monitoring due to their narrow margin of safety. On the contrary, medications with a very high TI (eg, penicillin) are generally safe. In&#x000a0;one study, the ED50 for a motor block of intrathecally administered bupivacaine was reduced with advancing age.<xref ref-type="bibr" rid="article-20894.r8">[8]</xref></p>
      </sec>
      <sec id="article-20894.s4" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>The ED50 is a metric representing the dose of a medication that produces the intended pharmacological effect in 50% of the patient population studied during clinical trials. This value is derived from clinical studies and is used to help clinicians determine the optimal initial dose for their patients.&#x000a0;An interprofessional team of physicians, pharmacists, nurses, and other healthcare professionals is&#x000a0;necessary&#x000a0;to monitor medication efficacy and safety according to patient factors, such as renal or hepatic function changes, disease state, and drug interactions, and ensure optimal patient outcomes.<xref ref-type="bibr" rid="article-20894.r9">[9]</xref></p>
      </sec>
      <sec id="article-20894.s5" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>According to the FDA, medications demonstrating a narrow therapeutic ratio, where the ratio between the median lethal dose (LD50) and median effective dose (ED50) is less than 2-fold, or when there is less than a 2-fold difference in minimum toxic concentrations and minimum effective concentrations in the bloodstream,&#x000a0;require careful titration and vigilant monitoring for safe and effective utilization.</p>
      </sec>
      <sec id="article-20894.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20894&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20894">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20894/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20894">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20894.s7">
        <title>References</title>
        <ref id="article-20894.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dimmitt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stampfer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>When less is more - efficacy with less toxicity at the ED50.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>83</volume>
            <issue>7</issue>
            <fpage>1365</fpage>
            <page-range>1365-1368</page-range>
            <pub-id pub-id-type="pmid">28387051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20894.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Fay</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Surrogate end-points in clinical practice: are we providing worse care?</article-title>
            <source>Intern Med J</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>395</fpage>
            <page-range>395-8</page-range>
            <pub-id pub-id-type="pmid">20636827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20894.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stampfer</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Gabb</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Dimmitt</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Why maximum tolerated dose?</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>85</volume>
            <issue>10</issue>
            <fpage>2213</fpage>
            <page-range>2213-2217</page-range>
            <pub-id pub-id-type="pmid">31219196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20894.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Konstam</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Neaton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dickstein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Drexler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Komajda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Riegger</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Malbecq</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Guptha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poole-Wilson</surname>
                <given-names>PA</given-names>
              </name>
              <collab>HEAAL Investigators</collab>
            </person-group>
            <article-title>Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.</article-title>
            <source>Lancet</source>
            <year>2009</year>
            <month>Nov</month>
            <day>28</day>
            <volume>374</volume>
            <issue>9704</issue>
            <fpage>1840</fpage>
            <page-range>1840-8</page-range>
            <pub-id pub-id-type="pmid">19922995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20894.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mouton</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Parrish</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Njuguna</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maartens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Blockman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>818</fpage>
            <page-range>818-26</page-range>
            <pub-id pub-id-type="pmid">25475751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20894.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Smyth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Steinhubl</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Aspirin dose for the prevention of cardiovascular disease: a systematic review.</article-title>
            <source>JAMA</source>
            <year>2007</year>
            <month>May</month>
            <day>09</day>
            <volume>297</volume>
            <issue>18</issue>
            <fpage>2018</fpage>
            <page-range>2018-24</page-range>
            <pub-id pub-id-type="pmid">17488967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20894.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamargo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Le Heuzey</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Mabo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2015</year>
            <month>May</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>549</fpage>
            <page-range>549-67</page-range>
            <pub-id pub-id-type="pmid">25870032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20894.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>The effect of age on the median effective dose (ED50) of intrathecally administered plain bupivacaine for motor block.</article-title>
            <source>Anesth Analg</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>118</volume>
            <issue>4</issue>
            <fpage>863</fpage>
            <page-range>863-8</page-range>
            <pub-id pub-id-type="pmid">24651241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20894.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krens</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Lassche</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jansman</surname>
                <given-names>FGA</given-names>
              </name>
              <name>
                <surname>Desar</surname>
                <given-names>IME</given-names>
              </name>
              <name>
                <surname>Lankheet</surname>
                <given-names>NAG</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>van Herpen</surname>
                <given-names>CML</given-names>
              </name>
              <name>
                <surname>van Erp</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.</article-title>
            <source>Lancet Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>e200</fpage>
            <page-range>e200-e207</page-range>
            <pub-id pub-id-type="pmid">30942181</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
